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he periprocedural management of patients with atherosclerotic coronary heart
isease, including those who have heart disease and those who are undergoing percutaneous
oronary intervention and stent placement who might require temporary interruption of platelet-
irected pharmacotherapy for the purpose of an elective endoscopic gastrointestinal procedure, is a
ommon clinical scenario in daily practice. Herein, we summarize the available information that
an be employed for making management decisions and provide general guidance for risk
ssessment.
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Antithrombotic Therapy and Gastrointestinal Procedures December 8, 2009:2261–76The estimated annual cost of
CHD approaches $170 billion.
The recent and steady decrease in
U.S. death rates from CHD has
been attributed in large part to
evidence-based medical treat-
ments, including platelet-directed
pharmacotherapies (also referred
to in the document as platelet an-
tagonists) (4).
The periprocedural manage-
ment of patients who might re-
quire temporary interruption of
platelet-directed pharmacother-
apy because of an endoscopic
gastrointestinal (GI) procedure
is a common clinical consider-
ation. The decision is challeng-
ing, because the risk of a
thrombotic event during inter-
ruption of therapy must be bal-
anced carefully against the risk
for bleeding when treatment is
administered in close proximity
to the procedure.
There are 2 fundamental ques-
tions that each clinician must ask:
1. Is interrupting platelet-directed
pharmacotherapy in the peripro-
cedural period necessary? This
question is particularly relevant
when the anticipated risk for
thrombosis is high and the
concomitant procedure-related
bleeding risk is low.
. If platelet-directed pharmacotherapy is interrupted, what is the
optimal timing and duration for temporary discontinuation?
The primary objectives of our collaborative white paper
re to: 1) summarize the available data and, when available,
ccompanying evidence for the risk of hemorrhagic and
hrombotic events associated with elective endoscopic GI
rocedures among patients with CHD—particularly those
ith coronary artery stents receiving platelet-directed phar-
acotherapy; 2) summarize the available data and, when
vailable, accompanying evidence for the risk of thrombotic
nd hemorrhagic events associated with elective endoscopic
I procedures among patients with CHD in whom
latelet-directed pharmacotherapy is interrupted for 5 or
ore days before and/or after the procedure; and 3) provide
irection for general risk assessment that allows practicing
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
BMS  bare-metal stent(s)
CHD  coronary heart
disease
CI  confidence interval
CV  cardiovascular
DES  drug-eluting stent(s)
ECG  electrocardiogram/
electrocardiographic
ERCP  endoscopic
retrograde
cholangiopancreatography
ESD  endoscopic
submucosal dissection
FNA  fine needle
aspiration
GI  gastrointestinal
MI  myocardial infarction
NSAID  nonsteroidal
anti-inflammatory agent
OR  odds ratio
PCI  percutaneous
coronary intervention
PPI  proton pump
inhibitor
RR  relative risk
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionlinicians to better identify and, whenever possible, quanti- wate (as low, medium, or high) individual patient risk for
ither continued or interrupted platelet-directed pharmaco-
herapy among patients with CHD undergoing elective
ndoscopic procedures.
The overarching goal is to provide an informative over-
iew for practicing clinicians that fosters a balanced ap-
roach to the care of patients with CHD undergoing
lective endoscopic GI procedures. We will not craft a
onsensus document; however, the clinically relevant infor-
ation is designed to build on the theme of reducing GI
isks of platelet-directed pharmacotherapy highlighted in
he 2008 ACCF/ACG/AHA Consensus Statement (5) and
rovide a concomitant CV risk perspective relating to
ithdrawing treatment in anticipation of an elective endo-
copic GI procedure.
V Risks
ual platelet antagonists in CV disease. Aspirin and
hienopyridines, such as clopidogrel, exert their platelet-
nhibiting effect through distinct mechanisms that target
eparate pathways. Laboratory and animal studies confirm a
ynergistic effect of these agents on platelet activation and
ggregation. In the last decade, data from large randomized
linical trials of patients with acute coronary syndrome
ACS) or those undergoing percutaneous coronary inter-
ention (PCI) have shown a significant reduction in CV end
oints with dual aspirin-thienopyridine therapy compared
ith aspirin alone. In this section we will review and
mphasize established indications (as per the ACC/AHA
anagement Guidelines) for a dual platelet antagonist
trategy and the accompanying designated level of evidence.
he anticipated safety of this strategy, particularly in rela-
ion to bleeding complications and relevant drug interac-
ions will also be summarized.
ndications for dual platelet antagonists in CV disease.
T-SEGMENT ELEVATION MYOCARDIAL INFARCTION
STEMI). Clopidogrel 75 mg/day orally should be added to
spirin in patients with STEMI regardless of whether they
ndergo fibrinolytic therapy or do not receive reperfusion
herapy (Class I, Level of Evidence: A). Treatment
hould continue for at least 14 days (Class I, Level of
vidence: B) (6).
The CLARITY–TIMI 28 (Clopidogrel as Adjunctive
eperfusion Therapy–Thrombolysis In Myocardial Infarc-
ion 28) trial compared the efficacy of clopidogrel (300 mg
ral loading dose, then 75 mg/day) plus aspirin (recom-
ended dose 150 to 325 mg on the first day and 75 to 162
g daily thereafter) with aspirin alone in 3,491 patients ages
75 years with STEMI receiving fibrinolytic therapy (7).
atients were treated up to the time of protocol-mandated
ngiography (day 2 to 8); the average duration of treatment
as 4 days (maximum 16 days). Dual therapy was associated
ith a 36% reduction in the composite end point of an
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December 8, 2009:2261–76 Antithrombotic Therapy and Gastrointestinal Proceduresccluded infarct-related coronary artery or death or MI
efore angiography could be undertaken (95% confidence
nterval [CI]: 27% to 47%, p  0.001) at 2 to 8 days. This
enefit was largely due to a lower rate of occlusion of the
nfarct-related artery (there was no significant reduction in
ither death or MI). By 30 days, patients given dual therapy
ad 20% lower odds of CV death, MI, or urgent revascu-
arization (14.1% vs. 11.6%, p  0.03). There was no
ifference in Thrombolysis In Myocardial Infarction
TIMI) major bleeding through the day of coronary angiog-
aphy (dual therapy 1.3% vs. aspirin alone 1.1%).
The COMMIT (Clopidogrel and Metoprolol in Myo-
ardial Infarction) trial, conducted in China, randomized
5,852 patients (26% of patients were older than 70 years of
ge) within 24 h of a suspected MI to clopidogrel 75 mg
initial loading dose) then 75 mg daily plus aspirin (162 mg
aily) or aspirin and placebo (8). Approximately 93% of
atients had STEMI (or a left bundle branch block pattern),
nd one-half received reperfusion therapy. The average
uration of treatment was 15 days. The risk of death,
einfarction, or stroke was decreased from 10.1% in the
lacebo arm to 9.2% in the treatment arm (odds ratio [OR]:
.91, 95% CI: 0.86 to 0.97). All cause mortality was
imilarly reduced in the treatment arm (8.1% vs. 7.5%, p 
.03). The rate of cerebral and major bleeding did not differ
etween the 2 treatment groups (0.58% vs. 0.55%).
ON-ST-SEGMENT ELEVATION ACS. For patients with un-
table angina/non-STEMI in whom an initial invasive
trategy is planned, antiplatelet therapy in addition to
spirin should be initiated before diagnostic angiography
ith either clopidogrel (loading dose followed by daily
aintenance dose) or intravenous glycoprotein (IIb/IIIa
nhibitor therapy (Class I, Level of Evidence: B) (4). For
atients undergoing PCI, clopidogrel in addition to aspirin
hould be continued for up to 1 year (at least 1 year in those
eceiving drug-eluting stents [DES]).
For patients with unstable angina/non-STEMI in whom
n initial conservative strategy is selected, clopidogrel (load-
ng dose followed by daily maintenance dose) should be
dded to aspirin and anticoagulant therapy as soon as
ossible after admission and administered for at least 1
onth (Class I, Level of Evidence: A) and ideally up to 1
ear (Class I, Level of Evidence: B) (9).
The CURE (Clopidogrel in Unstable Angina to Prevent
ecurrent Events) trial randomized 12,562 patients with
lopidogrel (300 mg oral load followed by 75 mg/day) and
spirin versus aspirin and placebo and followed them for 3
o 12 months (10). The composite end point of CV death,
I, or stroke occurred in 11.5% of patients receiving
lacebo vs. 9.3% of those receiving clopidogrel (relative risk
RR]: 0.80, 95% CI: 0.72 to 0.90). The observed difference
as largely due to a significant 23% reduction in recurrent tI, with weak trends for reductions in death (RR: 0.93,
5% CI: 0.79 to 1.08) and stroke (RR: 0.86, 95% CI: 0.63
o 1.18). These reductions were consistent across all pre-
pecified patient subgroups (positive and negative biomar-
ers, positive and negative electrocardiographic [ECG]
hanges, and TIMI risk score categories). In addition, there
as a 20% risk reduction in the composite end point in the
rst 30 days and beyond 30 days.
Major bleeding—defined as disabling bleeding, intraoc-
lar bleeding with visual loss, and/or bleeding prompting
he transfusion of 2 or more units of blood—was more
requent in clopidogrel-treated patients (3.7% vs. 2.7%, p 
.001). The rate of major bleeding, predominantly GI or at
he femoral access site, was higher both in the first 30 days
nd after 30 days. The risk of bleeding was particularly high
n patients who underwent coronary artery bypass grafting
ithin 5 days of clopidogrel therapy compared with those in
hom clopidogrel was held for at least 5 days (9.6% vs.
.3%, p  0.06).
In an observational study of CURE (PCI-CURE) (1),
ata from 2,658 patients who subsequently underwent PCI
ere analyzed. Patients were pretreated with aspirin and
tudy drug for a median of 6 days before PCI. After PCI
ost patients received open label thienopyridine for 4
eeks, and then blinded study drug was restarted for a mean
eriod of 8 weeks. At 30 days there was a significant
eduction (4.5% vs. 6.4%, p  0.03) in CV death, MI, or
rgent target vessel revascularization. Over long-term
ollow-up there was a 30% reduction in the composite end
oint in patients undergoing PCI who received clopidogrel
ompared with those receiving placebo. Increases in minor
ut not major bleeding were observed in patients receiving
lopidogrel.
CI AND STENTING. A loading dose of clopidogrel (in
ddition to aspirin) should be administered before PCI is
erformed (Class I, Level of Evidence: A) (11).
In patients who have undergone PCI, clopidogrel (in
ddition to aspirin) should be given for a minimum of 1
onth and ideally for up to 12 months after bare-metal
tent (BMS) implantation (unless the patient is at increased
isk for bleeding; then it should be given for a minimum of
weeks) (Class I, Level of Evidence: B) (11).
For all post-PCI patients receiving a DES, clopidogrel 75
g daily (in addition to aspirin) should be given for at least
2 months if patients are not at high risk of bleeding. (Class
, Level of Evidence: B) (11). Continuation of clopidogrel
herapy (in addition to aspirin) beyond 1 year may be
onsidered in patients undergoing DES placement (Class
Ia, Level of Evidence: C).
Early trials with the first-generation thienopyridine,
iclopidine, established the superiority of combined anti-
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Antithrombotic Therapy and Gastrointestinal Procedures December 8, 2009:2261–76latelet therapy initiated before PCI and continued for 30
ays over aspirin alone or aspirin plus warfarin, a vitamin K
ntagonist, to prevent early and late stent thrombosis after
CI (12–15). By virtue of a superior safety profile, similar
fficacy, and once/day dosing clopidogrel subsequently became
he thienopyridine of choice for this indication (16–18).
Subsequent trials have shown that extended treatment
ith aspirin and clopidogrel after PCI with stenting for
CS or after an elective procedure reduces CV events. The
esults of the PCI-CURE study have been reviewed previ-
usly. In the CREDO (Clopidogrel for the Reduction of
vents During Observation) trial, 2,116 patients undergo-
ng elective PCI were randomly assigned to receive 300 mg
lopidogrel versus placebo, followed by clopidogrel 75 mg
aily for 30 days (19). The initial loading-dose group
eceived clopidogrel 75 mg/day, and the control group were
iven placebo for the subsequent 12 months. All patients
eceived aspirin therapy. The composite end point of death,
I, or stroke at 12 months was decreased from 11.5% to
.5% (p  0.05) among patients receiving clopidogrel.
here was a trend toward an increased rate of major
leeding in the clopidogrel arm (8.8% vs. 6.7%, p  0.07).
HRONIC STABLE CORONARY ARTERY DISEASE. The cur-
ent American College of Cardiology/American Heart As-
ociation guidelines do not recommend dual antiplatelet
herapy in patients with documented coronary artery disease
nless there is a recent ACS (12 months) or PCI with
ES. In the CHARISMA (Clopidogrel for High Athero-
hrombotic Risk and Ischemia Stabilization, Management,
nd Avoidance) study (20), clopidogrel (75 mg/day) plus
spirin was compared with placebo and aspirin in 15,603
atients at high risk for CV events. Median follow-up was
8 months. Patients treated with clopidogrel had a similar
ate of the combined end point (MI, stroke, or CV death) as
atients in the placebo (aspirin alone) arm (6.8% vs. 7.3%,
R: 0.93, 95% CI: 0.83 to 1.05). Patients receiving dual
ntiplatelet therapy experienced higher rates of moderate
2.1% vs. 1.3%, p  0.001) and severe bleeding (1.7% vs.
.3%, p  0.09). In a subset of patients (n  9,478) with
rior MI, ischemic stroke, or symptomatic peripheral vas-
ular disease, dual antiplatelet therapy was associated with a
ower risk of the combined end point compared with aspirin
lone (hazard ratio: 0.83, 95% CI: 0.72 to 0.96) but with an
ncreased risk of bleeding.
otential drug interactions. Drug interactions between
spirin and clopidogrel are largely limited to the enhanced
otential for bleeding associated with each drug’s distinct
echanism of achieving platelet inhibition. In non-
nstrumented patients, most bleeding events are GI in
rigin. Aspirin is ulcerogenic by virtue of local injury to the
I mucosa and systemic depletion of prostaglandins. Al-hough not directly ulcerogenic, clopidogrel—by virtue of its ability to inhibit platelet activation and aggregation—
ight impair healing of small developing ulcers (5). The
ombined use of clopidogrel and nonsteroidal anti-
nflammatory drugs (NSAIDs), including aspirin, has been
ssociated with impaired healing of asymptomatic ulcers
nd with an increase in serious upper GI bleeding (21).
Proton pump inhibitors (PPIs) have been shown to
ecrease the risk of gastroduodenal ulcers and upper GI
leeding in patients taking aspirin or NSAIDs (22,23).
roton pump inhibitors also decrease the risk of GI bleed-
ng associated with the combination of clopidogrel and
spirin. In a matched case-control study of 2,777 consecu-
ive patients with upper GI bleeding and 5,532 control
ubjects, use of PPIs was associated with an 87%, 68%, and
1% reduction in risk of upper GI bleeding associated with
sers of NSAIDs, low-dose aspirin, and clopidogrel, respec-
ively. Accordingly, recommendations from an expert con-
ensus document supported the use of a gastroprotective
gent, preferably a PPI, for the prophylaxis of NSAID- and
spirin-associated GI injury (5). Proton-pump inhibitors are
ow commonly administered to patients at increased risk for
I bleeding who require dual antiplatelet therapy after
oronary stent placement.
There is increasing interest surrounding potentially im-
ortant interactions between PPIs and clopidogrel. These
edications share common metabolic pathways involving
epatic P450 isoenzymes, specifically 2C19. At least 1 study
uggested decreased platelet inhibition after coronary stent
mplantation among patients receiving PPIs in addition to
spirin and clopidogrel (24). In a retrospective cohort study
f 8,205 patients with ACS taking clopidogrel, the use of
PIs was associated with an increased risk of death or repeat
ospital stay for ACS (adjusted OR: 1.25, 95% CI: 1.11 to
.41) (25). Although observations from population-based
egistries and cohort studies are best interpreted as “hypoth-
sis generating,” further investigation must be undertaken to
rovide clarity around this very important area.
In the PRINCIPLE–TIMI 44 (Prasugrel in Comparison
o Clopidogrel for Inhibition of Platelet Activation and
ggregation–Thrombolysis In Myocardial Infarction 44)
rial (26), mean inhibition of platelet aggregation among
atients assigned to clopidogrel (600-mg oral loading dose)
as significantly lower (23.2  19% vs. 35.2  20%, p 
.02). There was a much more modest difference in patients
ssigned to prasugrel. The observations made in PRINCIP-
E–TIMI 44 did not translate to differences in clinical end
oints for patients participating in the TRITON–TIMI 38
TRial to assess Improvement in Therapeutic Outcomes by
ptimizing platelet inhibitioN with prasugrel–Thrombolysis
n Myocardial Infarction 38) trial. Accordingly, when clin-
cally indicated, PPIs should not be withheld.
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December 8, 2009:2261–76 Antithrombotic Therapy and Gastrointestinal Proceduresafety of discontinuing single agent and dual platelet
ntagonists. The risk of thrombotic events for patients
ith atherosclerotic disease is generally low after brief
essation of platelet antagonists. In contrast, the risk for CV
vents might be markedly increased among patients with an
nherent predisposition to thrombosis. The section will
ocus primarily on the patient group at greatest potential
isk for thrombotic events upon cessation of anti-
latelet therapy—those having undergone prior coronary
tenting.
UBSTRATES FOR STENT THROMBOSIS. The efficacy and
afety of DES are well-documented in clinical trials;
owever, animal studies and human autopsy data clearly
how a persistence of prothrombotic substrate for pro-
onged periods of time. Histopathological evaluation of
he vessel wall after DES implantation consistently re-
eals circumferential granulomatous inflammation con-
isting of macrophages, multinucleated giant cells, lym-
hocytes, and eosinophils adjacent to stent struts (27).
ibrin deposition within neointima and smooth muscle
ell apoptosis are frequently identified beyond 6 months
f implantation. The inflammatory response after BMS
mplantation is minimal and relatively brief in duration.
ndothelial cell injury and delayed and/or incomplete
ndothelialization of the stent struts are also important
eterminants of thrombogenicity.
EFINITION OF STENT THROMBOSIS. The Academic Re-
earch Consortium, in response to a request from the U.S.
ood and Drug Administration Circulatory System Device
Figure 1
Risk of Clinical Events After Clopidogrel Cessatio
isk-adjusted instantaneous incidence rates of death or acute myocardial infarction
eous coronary intervention (PCI)-treated patients with acute coronary syndrome. Re
cute myocardial infarction associated with stopping clopidogrel after acute coronaryanel’s recommendation to implement consensus defini-
ions for stent thrombosis in clinical trials, offered the
ollowing definitions (28):
Stent thrombosis may be classified as definite, probable,
or possible and as early (0 to 30 days), late (31 to 360
days), or very late (360 days).
Definite stent thrombosis requires the presence of an
ACS with either angiographic or autopsy evidence of
either occlusion or thrombus.
Probable stent thrombosis includes unexplained deaths
within 30 days after implantation or acute MI involv-
ing the original target vessel distribution.
Possible stent thrombosis includes all unexplained deaths
at least 30 days after the procedure.
Beyond its well-known initial and potentially catastrophic
eatures, coronary stent thrombosis has long-term clinical
mplications as well. The Dutch Stent Thrombosis Registry
29) reported recently on long-term clinical outcomes after
first angiographically confirmed stent thrombosis in 43
onsecutive patients. Cardiac death and/or definite recur-
ent stent thrombosis at 30 days, and 1, 2, and 3 years were
8%, 23.6%, 25.3%, and 27.9%, respectively (Fig. 1). The
iming of the first definite recurrent stent thrombosis among
5 patients with this complication was early in 54 patients,
ate in 15 patients, and very late in 6 patients, suggesting
hat a wide temporal range of stent thrombosis (and its risk)
pplies in multiple clinical settings.
me after stopping treatment with clopidogrel among medically treated and percuta-
with permission from Ho PM, Peterson ED, Wang L, et al. Incidence of death and
ome. JAMA 2008;299:532–9.n
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Antithrombotic Therapy and Gastrointestinal Procedures December 8, 2009:2261–76HROMBOTIC EVENTS IN THE FIRST MONTH AFTER
TENTING. What is the anticipated clinical impact of
topping aspirin or clopidogrel or both in the first 30 days
fter stenting? Although one can generally estimate the early
within 30 days of PCI) risk of stent thrombosis at 1% for
oth BMS and DES, there is a marked variation in risk,
epending upon clinical, procedural, treatment, and genetic
isk factors (Table 1) (28,30–33). The STARS (STent
nti-thrombotic Regimen Study) reported 30-day stent
Table 1
Risk Stratifcation for Early
and Late Stent Thrombosis
Variables
Low
Risk
Moderate
Risk
High
Risk
Cumulative absolute rate* 1% 2%–5% 6%
Absence of variables below x
Clinical risk factors
Prior stent thrombosis x
Presentation with ACS or STEMI x
Multivessel PCI x
Diabetes x
Renal failure x
Depressed ejection fraction x
Procedural risk factors
Diffuse coronary disease x
Smaller post-PCI diameter x
Multiple stents x
Residual dissection x
Bifurcation stenting x
Large thrombus burden x
First generation drug-eluting stents x
Drug-resistance factors
Cytochrome P450 variant x
Increased platelet reactivity x
Dual aspirin and clopidogrel
nonresponsiveness
x
Time-related factors
4 weeks of DPA x
Aspirin alone for 30 days x
Noncardiac surgery early after PCI x
With platelet antagonist therapy.
ACS  acute coronary syndrome; DPA  dual platelet antagonists; PCI  percutaneous
oronary intervention; STEMI  ST-segment elevation myocardial infarction.hrombosis incidence rates of 3.6% and 0.5%, respectively, tor patients with BMS receiving aspirin alone versus those
iven dual antiplatelet therapy (15). In contrast, several trials
nd registries have demonstrated an increased risk of 30-day
tent thrombosis solely in high-risk patient groups. Non-
ompliance with dual antiplatelet therapy is a consistent risk
actor for early stent thrombosis (31,32).
A large European registry identified bifurcation lesions,
enal failure, diabetes, lower ejection fraction, and longer
tent length (31) as predictors of early DES thrombosis but
id not identify factors such as diffuse coronary artery
isease, higher hemoglobin levels (32), or initial thrombus
urden (34). Each risk factor would potentially increase the
TARS trial estimate (3.6%) for stent thrombosis in the
rst 30 days after BMS with aspirin therapy alone.
Aspirin withdrawal might be associated with an increased
isk of ACS, especially STEMI (35,36). In addition, surgi-
al procedures (with aspirin or clopidogrel or both discon-
inued) performed in the first 2 to 4 weeks after stenting
ave reported up to a 30% rate of major adverse CV events
37–40). The early risk is similar for both BMS and DES
37). Thus, stopping both aspirin and clopidogrel for even a
rief period of time among patients within 30 days of stent
lacement is accompanied by risk.
ISK FOR LATE AND VERY LATE STENT THROMBOSIS. His-
ological studies have demonstrated uniform and complete
ndothelial coverage of BMS 30 days after stent implan-
ation. Conversely, a higher stent thrombosis risk is main-
ained during the 3-month to 3-year period of follow-up
ith DES as compared with BMS, potentially related to
elayed endothelialization of DES (41). Thus, there might
e an advantage to prolonged dual antiplatelet therapy for at
east 1 year after DES. In an observational study of over
,000 patients, continued use of clopidogrel beyond 6
onths did not influence death or MI rates from 6 to 24
onths after BMS placement. In contrast, continued use of
lopidogrel reduced death or MI rates between 6 and 24
onths after insertion of a DES (42). Randomized data are
equired to provide clarity for practicing clinicians.
HROMBOTIC EVENTS IN THE ABSENCE OF PRIOR PCI. The
HARISMA trial randomized stable patients with known
therosclerosis or multiple coronary risk factors to aspirin/
lopidogrel versus aspirin alone (1). Among patients with
ocumented prior MI, ischemic events were 23% higher
ith aspirin alone as compared with dual antiplatelet ther-
py (8.3% vs. 6.6%, p  0.01). These events accrued over
.5 years, yet there seemed to be a small but significant
azard for thrombotic events even 30 days after randomiza-
ion among patients receiving single antiplatelet therapy.
he Kaplan-Meier curves from the CHARISMA trial
emonstrate confirmed thrombotic events in 1% of pa-
ients managed with aspirin alone in the first month after
andomization. Accordingly, the overall risk of spontaneous
hrombotic events in patients with established coronary
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December 8, 2009:2261–76 Antithrombotic Therapy and Gastrointestinal Proceduresrtery disease receiving aspirin alone is low. In contrast, the
isk of withdrawing all antiplatelet therapy might not be
qually low, because “aspirin withdrawal” has been associ-
ted with acute coronary events clustered soon after aspirin
iscontinuation (average time from aspirin cessation to
vent  10 days) (35,36).
ESSATION OF PLATELET ANTAGONISTS: WHEN IS IT
AFE? Among patients receiving DES, discontinuing clopi-
ogrel within the first 6 months after PCI is associated with
heightened risk of stent thrombosis. In addition, stent
hrombosis tends to occur shortly after discontinuing any
ntiplatelet agent, with a median interval of 7 to 14 days
interquartile range 5.2 to 25.7 days) (43). The discontinu-
tion of both aspirin and a thienopyridine is associated with
particularly high risk for stent thrombosis. In the
-Cypher Registry (44), patients who discontinued both
spirin and either ticlopidine or clopidogrel had a signifi-
antly higher rate of stent thrombosis than those who
ontinued dual platelet-directed therapy between 31 and
80 days, 181 and 365 days, and 366 and 548 days (1.76%
s. 0.1%, p  0.001; 0.72% vs. 0.07%, p  0.02; and 2.1 vs.
.14%, p  0.004), respectively.
Eisenberg et al. (45) performed a systematic overview of
eported cases of late stent thrombosis and very late stent
hrombosis (Academic Research Consortium defined “def-
nite” cases). A total of 161 cases were identified. Patients
ho discontinued both aspirin and a thienopyridine had a
edian time to an event of 7 days. In those who discontin-
ed a thienopyridine but remained on aspirin, the median
ime to an event was 122 days. There were a total of 6 cases
6%) of stent thrombosis within 10 days of thienopyridine
essation, suggesting that short-term discontinuation be-
ween 30 days and 1 year from DES placement might be
elatively safe but by no means risk free.
A practical approach to minimizing CV risk can be
ummarized as follows:
Cessation of all antiplatelet therapies after PCI, at any
time, for any stent, is associated with an increased risk
of thrombotic events, including late stent thrombosis.
These events are likely to occur within 7 to 30 days of
drug discontinuation.
Cessation of clopidogrel (alone) during the early period
after PCI (within 30 days of either DES or BMS
placement) is associated with an increased risk of
thrombotic events.
Cessation of clopidogrel (alone) beyond 30 days from the
time of BMS placement is common in clinical practice
and does not confer increased risk of thrombosis over
a brief period of time. There is likely benefit from
more prolonged dual platelet antagonists among pa-
tients with ACS undergoing PCI. (Cessation of clopidogrel (alone) upon completion of 6
months of treatment after DES placement is contro-
versial (in terms of long-term risk) but does not seem
to confer a significant short-term risk (within the
subsequent 30 days) in a majority of patients if aspirin
is continued.
The potential importance of continued aspirin therapy is
upported by a recent structured overview of all reported
ases of late stent thrombosis: the median time to an event
as 7 days if both platelet antagonists were discontinued
nd 122 days if only the thienopyridine was stopped (34).
NTERRUPTION OF PLATELET ANTAGONIST THERAPY:
HARMACODYNAMIC CONSIDERATIONS. For patients who
re receiving aspirin, clinicians intending no antiplatelet
ffect at the time of a procedure should interrupt therapy for
to 10 days. Although aspirin has a plasma half-life of 15
o 20 min, it irreversibly and near-completely inhibits
latelet cyclooxygenase-1 activity, and therefore, the phar-
acodynamic effect persists for 7 to 9 days. Consequently,
to 5 days after cessation of aspirin, 50% of circulating
latelets will have normal cyclooxygenase-1 activity,
hereas after 7 to 10 days 90 of platelets exhibit normal
hromboxane A2 synthesis and aggregation response. San-
illi et al. (46), in a study of 48 healthy volunteers random-
zed to receive aspirin 100 mg daily for 1 to 8 weeks,
ighlighted a nonlinear relationship between inhibition of
hromboxane production and inhibition as gauged by plate-
et function assays. This observation offers clinical relevance
o recovery kinetics after aspirin cessation, wherein platelet
unction measurements might return to normal in several
ays, whereas serum thromboxane B2 levels do not recover
ntil 7 days.
In patients who are receiving clopidogrel or ticlopidine, a
hienopyridine derivative that causes noncompetitive plate-
et P2Y12 receptor inhibition, similar pharmacodynamic
rinciples to those of aspirin apply—with up to 10 days
eing required to replenish a normal platelet pool (47).
Unlike aspirin, clopidogrel and ticlopidine are pro-drugs
hat require a 2-step conversion to an active metabolite,
hich subsequently inhibits the P2Y12 receptor. The rela-
ive plasma concentrations of the active metabolite are low,
ermitting some receptors to remain unoccupied. Consid-
red collectively, 5 days might be a sufficient amount of time
or the restoration of an adenosine diphosphate-mediated
latelet response. In contrast, the plasma concentration of
rasugrel’s active metabolite is high, suggesting that a
omplete turnover of the circulating platelet pool, approxi-
ately 7 to 9 days, would be required to restore function-
lity (this distinction is the basis for differing recommenda-
ions for withholding treatment in proximity to coronary
ypass grafting). An abbreviated course of drug interruption
3 days) might be sufficient with the reversible, non-
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or (48). Cilostazol is a phosphodiesterase inhibitor with
ntiplatelet and vasodilatory properties that reversibly affects
latelet function through cyclic adenosine monophosphate-
ediated inhibition of platelet activation and aggregation.
ilostazol may be used in patients with CHD, particularly
hose with coronary arterial stents, or peripheral arterial
isease. The pharmacokinetics of cilostazol are dose-
ependent, with an elimination half-life of approximately
0 h. Consequently, this drug would need to be interrupted
or approximately 3 days (corresponding to 5 elimination
alf-lives) before a procedure is performed that poses a risk
or hemorrhage.
Additional investigations of the temporal sequence of
latelet-mediated biological events—including onset, offset, dura-
ion of effects, and mechanism of action for all platelet antagonists,
o include newly developed agents such as ticagrelor—will ulti-
ately prove useful for clinicians worldwide.
trategies for bridging and restarting platelet antagonist
herapy. BRIDGING THERAPY. Although the interruption
f platelet antagonists for elective GI procedures—
articularly among individuals at risk for stent thrombosis—
hould not be a common occurrence, management options
re important for practicing clinicians.
As summarized in prior sections, interruption of oral
latelet antagonists for scheduled procedures has been
ssociated with increased 30-day mortality (36). The poten-
ial risk, on the basis of observational studies and registries,
as not been influenced favorably or lessened by heparin
ridging (36,49).
The periprocedural administration of glycoprotein IIb/
IIa receptor antagonists, although representing a more
iologically sound approach than anticoagulant therapy
50), lacks randomized effectiveness and safety data. Short-
cting platelet P2Y12 inhibition with reversible agents like
angrelor or ticagrelor (not available for clinical use at the
resent time) or an alternative compound with similar
roperties of target selectivity and a very short biological
alf-life represents the most attractive platform for bridging
herapy. The BRIDGE (Maintenance of Platelet inihiBition
ith cangRelor After dIscontinuation of ThienopyriDines in
atients Undergoing surgery) trial (ClinicalTrials identifier:
CT00767507) will compare cangrelor and placebo among
00 patients in whom a thienopyridine drug is discontinued
efore coronary artery bypass grafting.
ESTARTING PLATELET ANTAGONISTS. In patients who
ave temporary interruption of platelet antagonists before
lective endoscopic procedures, treatment should be resumed
s soon as possible afterward. A common question is whether
esumption of treatment should be with a maintenance dose,
hich achieves maximal effect in several days, or with a loading
ose that more rapidly produces platelet inhibition. The choice df loading dose might not be a major determinant of major
leeding risk (51). The dose of clopidogrel (300 mg or 600 mg)
hould be gauged by individual patient risk, to include the
resence of a coronary stent, the type of stent (BMS or DES),
nd how recently the stent was placed.
OTENTIAL ROLE FOR POINT-OF-CARE PLATELET FUNCTION
ESTING. In addition to traditional laboratory-based platelet
ggregation tests, several point-of-care (whole-blood) platelet-
onitoring devices are available for clinical use (52). An
ngoing clinical trial, the GRAVITAS (Gauging Responsive-
ess with A VerifyNow Assay-Impact on Thrombosis and
afety) trial (53) is testing whether platelet-function guided
lopidogrel therapy can reduce major adverse cardiac events
fter DES placement. In contrast, the use of either laboratory-
ased or point-of-care platelet aggregation measurement plat-
orms to gauge bleeding risk associated with surgical (or
ndoscopic) procedures remains poorly defined. Accordingly,
either is recommended as a routine “screening test” before
lective endoscopy.
I Risks
ardiopulmonary complications of elective GI endoscopy.
he potential for cardiopulmonary complications inherent
o endoscopy must be considered when assessing the relative
isk of discontinuing platelet antagonists in preparation for
he procedure. These risks, although generally low, might be
elated to anxiety/stress generated by the procedure itself,
he effects of medications used to achieve sedation, or the
reparation (in particular for colonic purgatives). The im-
ortance of individual patient risk assessment must be
mphasized, as illustrated by reports of renal dysfunction
ith phosphate containing cathartics, leading to their recent
emoval from the U.S. market (Table 2).
There is significant variation in the reported rates of cardio-
ulmonary complications associated with endoscopy. Most of
he reports have focused on the consequences of sedation and
nalgesia. In a retrospective review of 21,011 procedures, the
omplication rate was reported as 5.4 of 1,000 procedures, with
death rate of 3 of 10,000 (54). In a prospective survey of
4,149 gastroscopies, the calculated rate of complications
ncluding the 30-day post-procedure period was 2 of 1,000.
here were 11 patients (8 deaths) with pneumonia (presumed
o be related to aspiration), 3 patients (3 deaths) with pulmo-
ary emboli, and 19 patients (14 deaths) with acute MI. The
verall death rate was 1 of 2,000 (55).
In a survey of 25,298 colonoscopies, MI was reported in
.012% of patients (56). In studies specifically involving
olonoscopy, ECG changes have been reported in 41% to 65%
f patients (57). A study of ECG changes during assessment of
00 patients undergoing rigid sigmoidoscopy reported prema-
ure ventricular complexes in 40% of patients with cardiac
isease and in 17% of patients without a cardiac history (58).
d
c
n
r
d
p
o
b
O
c
r
p
a
m
b
p
b
m
p
w
i
p
0
p
v
i
a
w
s
b
c
r
p
t
s
h
w
e
i
fl
E
t
p
c
a
e
b
o
T
m
o
i
w
c
o
d
r
e
l
e
w
u
b
g
(
a
l
m
percut
2269JACC Vol. 54, No. 24, 2009 Becker et al.
December 8, 2009:2261–76 Antithrombotic Therapy and Gastrointestinal ProceduresCardiopulmonary complications associated with GI en-
oscopy, as mentioned previously, have several possible
ontributing factors. Sedative medications, in particular the
arcotics, exert dose-related and inhibitory effects on respi-
ations and blood pressure. Air insufflation can cause bra-
ycardia and hypotension from vagally mediated effects. In
atients with coronary artery disease, hypoperfusion might
ccur due to endoscopy or medication-related changes in
lood pressure, heart rate, and oxygenation saturation.
xygen desaturation is a well-recognized risk factor for
ardiac arrhythmias (59,60). In addition, catecholamine
elease secondary to dehydration, anxiety, and pain are
ossible mechanisms. Vagal stimulation, generated through
stretching of the hollow viscus (through air insufflation or
echanical distention related to the endoscope) might also
e a plausible explanation in some patients.
Oral colonic purgative lavage solutions are widely used to
repare patients for colonoscopy. Cardiac arrhythmias have
een reported in patients undergoing continuous ECG
onitoring during both the preparation and procedure
hases of colonoscopy. In 1 small study, 12 of 24 patients
ho were hospitalized for other reasons, demonstrated an
ncrease in ventricular premature contractions during the
reparation phase compared with the control period (p 
.01). Two patients demonstrated ventricular tachycardia, 4
atients manifested complex ventricular ectopy without
entricular tachycardia, and 6 patients demonstrated an
ncrease in simple premature ventricular contractions. The
uthors concluded that peroral colonic lavage was associated
ith increased ventricular ectopy (61). Administration of
odium phosphate products is an alternative for catharsis
efore colonoscopy. Changes in serum sodium, potassium,
hloride, calcium, ionized calcium, and inorganic phospho-
ous levels have been noted in some patients after sodium
Table 2
Gastrointestinal Procedures Conside
High Risk
Polypectomy D
Biliary sphincterotomy F
Pneumatic or bougie dilation C
PEG placement E
Endoscopic ultrasound-guided fine needle aspiration B
Laser ablation and coagulation E
Treatment of varices E
Adapted from Zuckerman MJ, et al. (84).
ERCP  endoscopic retrograde cholangiopancreatography; PEG hosphate preparation when compared with values before she preparation. Fatalities due to significant fluid shifts,
evere electrolyte abnormalities, and cardiac arrhythmias
ave been rarely reported (62). To minimize risk, patients
ith underlying CV and renal disease are prescribed poly-
thylene glycol colonic lavage solution for preparation and
nstructed to avoid dehydration by ingestion of additional
uids to maintain appropriate volume status.
ndoscopy-related GI bleeding. In assessing the risks of
emporary discontinuation of platelet antagonists for a
atient with CV disease who is undergoing elective endos-
opy, it is important to assess the inherent risk of bleeding
ssociated with the procedure. Although generally consid-
red overall low-risk, GI endoscopy does increase the risk of
leeding. The risk varies with procedure type and whether
r not associated therapeutic interventions are performed.
he published reports assessing this risk have significant
ethodological limitations, being composed almost entirely
f surveys and small case series, as recently reviewed (63). It
s generally accepted that all diagnostic procedures with or
ithout mucosal biopsy as well as endoscopic retrograde
holangiopancreatography (ERCP) without sphincterot-
my, diagnostic balloon-assisted enteroscopy, and en-
osonography without tissue sampling are low-risk. High-
isk procedures with an increased risk of bleeding include
ndoscopic polypectomy or endoscopic mucosal resection,
aser ablation, therapeutic balloon-assisted enteroscopy, and
ndoscopic sphincterotomy. Those therapeutic procedures
ith the potential to produce bleeding that is inaccessible or
ncontrollable by endoscopic means, such as dilation of
enign or malignant strictures, percutaneous endoscopic
astrostomy, endosonography-guided fine needle aspiration
FNA) or tru-cut biopsy are considered high-risk (64).
Colonoscopy is the most commonly performed diagnostic
nd therapeutic procedure in current clinical practice, and
arge cohort studies provide valuable information for deter-
ining procedure-related risks. A recent population-based
High and Low Risk for Bleeding
Low Risk
stic esophagogastroduodenoscopy with or without biopsy
sphincterotomy with or without biopsy
scopy with or without biopsy
ithout endoscopic sphincterotomy
pancreatic stent without sphincterotomy
opic ultrasound without fine needle aspiration
copy
aneous endoscopic gastrostomy.red
iagno
lexible
olono
RCP w
iliary/
ndosc
nterostudy in Canada of 97,091 patients undergoing outpatient
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Antithrombotic Therapy and Gastrointestinal Procedures December 8, 2009:2261–76olonoscopy reported the occurrence of bleeding in 1.64 of
,000 procedures. Older age, male sex, performance of a
olypectomy, and the procedure being performed by a
ow-volume endoscopist were factors associated with an
ncreased risk of a complication (65).
Colonoscopic polypectomy carries a low bleeding risk, in
he range of 0.4% to 3.4%, but the risk increases with polyp
ize 10 mm (adjusted OR: 4.5; 95% CI: 2.0 to 10.3) (66)
nd might be influenced by technique, polyp morphology,
nd location. Endoscopic biopsy or polypectomy can induce
types of bleeding: immediate, which can usually be
ontrolled during the procedure; and delayed, occurring up
o 30 days later (67). Considered collectively, the rate for
oth types of bleeding associated with colonoscopic
olypectomy has been reported to be 1% (68).
Some patients are at higher risk of bleeding; these include
lderly persons and patients with chronic comorbid condi-
ions such as hypertension, diabetes, coronary artery disease,
nd chronic obstructive pulmonary disease. Advancing age
ncreases the likelihood of a requirement for blood-
ransfusion after post-polypectomy bleed (69), and patients
ith systemic hypertension experience a 5-fold increased
isk of delayed post-polypectomy bleed (66). In a recent post
oc analysis of a case-control study, diabetes (OR: 2.5; 95%
I: 1.2 to 5.1), coronary artery disease (OR: 3.0; 95% CI:
.5 to 6.2), and chronic obstructive pulmonary disease (OR:
.2; 95% CI: 1.1 to 4.8) were associated with delayed
ost-polypectomy bleeding, but the risk was attenuated after
djusting for anticoagulant use (70).
Immediate post-polypectomy bleeding is more common
ith cutting or blended current, and delayed bleeding is
ore common with coagulation current, which might create
deeper ulcer at the polypectomy site and is particularly
elevant to the risk associated with the use of a hot biopsy
orceps. Immediate hemorrhage may be treated with injec-
ion of epinephrine followed by multipolar cautery or
lipping, and the endoscopist can almost invariably achieve
emostasis. Delayed bleeding classically presents as passage
f large-volume bloody bowel movements and can occur up
o 21 days after polypectomy. Risk factors for hemorrhage
nclude large polyp size and location in the proximal colon
70). Immediate bleeding after cold forceps or cold snare
emoval of small polyps is nearly always capillary in nature
nd clinically insignificant. Because this approach success-
ully achieves polyp removal and is associated with a lower
isk of bleeding than hot biopsy forceps, it is the recom-
ended strategy to minimize complications (71).
Bleeding from diagnostic esophagogastroduodenoscopy is
ncommon and estimated to occur in 1 of 1,000 procedures or
ess according to publications from the 1970s and 1980s.iagnostic endoscopy occasionally causes bleeding from iatro- senic Mallory-Weiss tears or endoscopic biopsies. Therapeutic
rocedures, such as sclerotherapy or gastroduodenal polypec-
omy, are associated with much higher bleeding complication
ates. For example, bleeding complications from gastroduodenal
olypectomies have been reported in 0.2% to 8% of procedures—a
ate that is similar to colonoscopic polypectomy (63).
Esophageal dilation can be performed in the upper GI tract
ith tapered “over the wire” dilators or through the endoscope
alloon dilation, which can also be employed at any site within
each of an endoscope. The risk of bleeding after dilation is
1%—typically at the site of mucosal tears or abrasions at site
f dilation. The risk of bleeding is increased when dilations are
erformed for malignant stenoses. Overall, the bleeding is
ypically self-limited, and the type of dilator used is probably
ess important than the experience of the primary endoscopist
n using a given device (71).
Treatment of esophageal varices with banding and/or
clerotherapy can initiate bleeding, but this is usually man-
ged at the time of the therapeutic procedure. The place-
ent of a percutaneous gastrostomy has been associated
ith rates of bleeding in the range of 0.2% to 2.5% and is
enerally related to the initial skin puncture for tube passage
r as a result of delayed ulceration at the stoma site (72).
Endoscopic sphincterotomy at ERCP can cause bleeding.
he overall risk has been estimated at 5% and can be
elayed as well as life-threatening (73). Endoscopic ultra-
ound without FNA has a risk of bleeding similar to
sophagogastroduodenoscopy, whereas FNA has a risk of
leeding estimated in the range of 2% (74). Endoscopic
ucosal resection, where large areas of tissue are removed
ith a variety of techniques, is increasingly used in the U.S.
or removal of Barrett’s esophagus with high-grade dysplasia
r early cancer. It can be used in other parts of the GI tract
s well. Bleeding is the most common complication of this
rocedure, generally in the range of 10% in large series (74).
haracterization of bleeding risk associated with platelet
ntagonists. The attributable risk of post-endoscopic
leeding among patients taking platelet antagonists remains
oorly characterized. Although it is assumed that these
gents increase the risk of post-procedure bleeding, few
onfirmatory studies have been undertaken.
leeding risk associated with a single platelet antagonist.
SPIRIN. Several studies have assessed the risk of post-
rocedure bleeding attributable to aspirin. In the absence of a
re-existing bleeding disorder, it is reasonable to perform
lective endoscopic procedures in patients taking aspirin or
ther NSAIDs. Two studies have demonstrated that aspirin is
ot associated with an increased risk of post-procedure bleed-
ng (75,76). Furthermore, the current published data support
he safety of continued aspirin administration in the periendo-
copic period, even after high-risk endoscopic procedures such
s polypectomy (70,75,77) or sphincterotomy (78,79). That
aid, the available data are limited to retrospective observational
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olypectomy bleeding that fails to reach statistical significance
75). Yousfi et al. (77) observed higher rates of post-
olypectomy bleeding among patients who ingested aspirin
ithin 3 days of colonoscopic polypectomy when compared
ith control subjects (40% vs. 33%); however, they failed to
emonstrate a statistically significant association between aspi-
in and post-endoscopic bleeding complications (OR: 1.4; 95%
I: 0.6 to 3.0). In a large retrospective study of 4,592 patients
ho underwent colonoscopic polypectomy, aspirin use (de-
ned as at least 1 dose within 1 week before and 1 week after
olypectomy) was not found to be a clinically significant
redictor of post-polypectomy bleeding (OR: 1.1; 95% CI: 0.5
o 2.2, p  0.8) (70).
Two small-scale, retrospective studies assessed the risk of
leeding after endoscopic sphincterotomy in patients receiving
latelet antagonists, with mixed results. Among 40 patients
xposed to a platelet antagonist, including aspirin, clopidogrel,
r ticlopidine, 16% had been exposed before the endoscopic
phincterotomy (13% taking aspirin, and 3% taking clopi-
ogrel). After adjusting for possible confounders (i.e., presence
f coagulopathy and cholangitis), exposure to a platelet antag-
nist did not significantly increase the risk of clinically impor-
ant procedure-related bleeding after endoscopic sphincterot-
my (OR: 0.41; 95% CI: 0.13 to 1.31) (78). In contrast, a
econd retrospective study reported an increased risk of bleed-
ng after endoscopic sphincterotomy in patients taking aspirin
p to the day of the procedure versus those who did not take
spirin (9.7% vs. 3.9%, OR: 2.1; 95% CI: 1.1 to 4.0; p 0.01)
73). However, in addition to the case-control design, limita-
ions of these studies include an unclear definition of bleeding,
statistical analysis that did not adequately adjust for possible
ofounders, and lack of statistical power (79).
LOPIDOGREL. Clopidogrel causes irreversible platelet in-
ibition, and upon drug cessation, a return of platelet
ggregation to at least 50% of normal requires a minimum
f 5 days (80,81). Although it is uncertain whether clopi-
ogrel causes direct mucosal injury (82), it is associated with
n increased risk of GI bleeding.
The published data do not provide an accurate gauge for
etermining the risk of bleeding associated with clopidogrel
or ticlopidine) after an endoscopic procedure. Although 1
etrospective study attempted to discern the effects of
lopidogrel, only 3% of patients received the agent (vs. 13%
eceiving aspirin), limiting conclusions for its safe use before
ndoscopic sphincterotomy (79). Clopidogrel has been as-
ociated with an increased risk of bleeding in non-GI
nvasive procedures. For example, moderate or severe bleed-
ng after trans-bronchial lung biopsy occurred in 61% of
lopidogrel-treated patients compared with 1.8% among
ontrol subjects (83). Current guidelines recommend with- tolding clopidogrel for at least 7 days for patients with a
lanned high-risk endoscopic procedure (64,84).
Patients in whom the risk of a CV event, particularly stent
hrombosis, is high should have elective endoscopic procedures
eferred until clopidogrel can be safely discontinued. Emergent
rocedures should be undertaken as the clinical circumstances
ictate. Strategies to reduce the risk while receiving antiplatelet
herapy are discussed in the following text.
There is currently no experience with prasugrel or ticagrelor.
leeding risk associated with dual platelet antagonists.
lthough the risk of bleeding after an endoscopic procedure
n patients prescribed dual platelet antagonists with aspirin
nd clopidogrel is unknown, their effects on the GI tract
ave been studied. Dual platelet antagonists significantly
ncrease the risk of GI bleeding when compared with
onotherapy (10,21,85) and also impair the healing of
lcers (23). The addition of clopidogrel to aspirin increases
he relative risk of GI bleeding by up to 70% (86).
herefore, in patients prescribed clopidogrel plus aspirin,
topping clopidogrel (and continuing aspirin) before per-
orming a high-risk elective endoscopy likely reduces bleed-
ng risk (discussed in the next section).
trategies to reduce the risk of endoscopic procedures for
atients receiving platelet antagonists. Although current
merican Society for Gastrointestinal Endoscopy guide-
ines recommend withholding non-aspirin platelet antago-
ists and anticoagulants for 7 to 10 days before elective
igh-risk endoscopic procedures (84), the potential impact
f this strategy on reducing the risk of bleeding is uncertain.
n a case series of 408 patients who underwent endoscopic
ubmucosal dissection (ESD) for early gastric cancer, post-
perative bleeding that required endoscopic treatment oc-
urred in 10.7% of patients in whom platelet antagonists or
nticoagulant therapy had been withheld for 1 week before
nd 1 week after tumor removal. In contrast, only 5.2% of
atients without prior exposure to platelet antagonists or
nticoagulant therapy had postoperative bleeding (although
he difference did not reach statistical significance) (87).
Limited data have suggested that prophylactic PPI ther-
py reduces the risk of delayed hemorrhage after endoscopic
emoval of large gastric mucosal lesions. A randomized trial
f ESD of early gastric cancer reported that oral PPI given
day before and for 8 weeks after ESD significantly reduced
he risk of bleeding complications (88).
Although data are lacking, patients receiving dual platelet
ntagonists are probably at higher risk of bleeding after an
ndoscopic procedure. If long-term dual platelet antagonist
herapy is anticipated (e.g., placement of a DES), physicians
hould advise these patients to consider elective endoscopic
rocedures before the cardiac intervention—provided that
hey are clinically stable.
The bleeding risk after polypectomy of small polyps (1
m) in anticoagulated patients might potentially be reduced by
he application of prophylactic clips (89–91). However, no
r
b
a
s
d
w
d
J
b
p
a
l
p
o
u
i
s
p
m
w
p
t
t
b
p
s
n
i
i
n
r
t
c
p
a
n
m
r
s
d
p
b
i
a
d
c
r
t
a
a
a
a
p
m
a
r
b
t
p
a
b
n
c
s
p
r
c
a
s
t
c
v
i
l
s
i
t
e
t
b
m
c
S
a
g
t
t
a
o
a
t
p
i
b
m
m
r
c
2272 Becker et al. JACC Vol. 54, No. 24, 2009
Antithrombotic Therapy and Gastrointestinal Procedures December 8, 2009:2261–76andomized controlled trials have been performed in patients
eing actively treated with antithrombotic agents (platelet
ntagonists or anticoagulants). One randomized, controlled
tudy of 413 average risk patients did not show a decrease in
elayed bleeding, although the mean polyp size in this study
as 7.8 mm (89). Similar studies evaluating the efficacy of
etachable snare devices (e.g., Endoloop, Olympus, Tokyo,
apan) as well as clips for the prevention of post-polypectomy
leeding have been done in average-risk patients but not in
atients using antithrombotics (89,90–94). Because of the
bsence of strong clinical data, routine application of prophy-
actic mechanical clips or detachable snares in anticoagulated
atients or those receiving antiplatelet agents cannot be rec-
mmended at this time. The studies reported to date have been
nderpowered to assess the risk–benefit relationship of these
nterventions and their overall cost-effectiveness, but they
hould be considered on a case-by-case basis for high-risk
atients. The use of “state-of-the-art” techniques for manage-
ent of large polyps, including injection with saline with or
ithout dilute epinephrine—particularly for large polyps or
iecemeal removal of polyps (and endoscopic mucosal resec-
ion as well)—seems to enhance the safety of these advanced
echniques for neoplasm resection.
Currently, there are limited data for the management of
leeding complications after elective endoscopic procedures in
atients receiving platelet antagonists. The choice of endo-
copic hemostatic therapy for bleeding complications and the
ature of the post-endoscopy care provided can only be
nferred from indirect evidence. A single study reported an
ncrease in serum epinephrine concentration 4- to 5-fold, with
ormalization in 20 min after endoscopic injection of epineph-
ine for bleeding peptic ulcers (95). Although CV complica-
ions were not reported, the study design did not permit a
omprehensive safety evaluation of epinephrine injections in
atients at high CV risk. Continuous ECG monitoring is
dvisable if a large volume of epinephrine injection is deemed
ecessary in patients with known CHD. Alternatively, use of a
ore diluted epinephrine solution or substitution of epineph-
ine by other endoscopic hemostatic methods (e.g., clips)
hould be considered. After achieving endoscopic hemostasis, a
ecision that considers the continuation or reintroduction of
latelet-directed pharmacotherapy must be made. In a double-
lind, randomized, placebo-controlled trial of aspirin therapy
n patients with CHD complicated by bleeding peptic ulcers,
ll patients underwent endoscopic therapy followed by high-
ose proton-pump inhibitor infusion. The group receiving
ontinuous low-dose aspirin had a 2-fold increase in 30-day
isk of rebleeding compared with the group without aspirin
herapy for the entire study period (96). In this study, however,
spirin cessation was associated with a significant increase in
ll-cause mortality and a trend toward a greater occurrence of rdverse CV outcomes. Thus, prolonged cessation of platelet
ntagonists in patients with known CHD and bleeding com-
lications after an elective endoscopic procedure is not recom-
ended. Although it remains to be proven, withholding
spirin for 3 to 5 days might reduce the likelihood of early
ebleeding after initial hemostasis (e.g., post-polypectomy
leeding), whereas the residual antiplatelet effects might con-
inue to provide CV protection.
Management of bleeding complications after endoscopic
rocedures in patients receiving dual platelet antagonists is
major challenge, because it requires careful assessment of
oth bleeding and thrombotic risks. The decision often
eeds to be individualized. If there is a major bleeding
omplication (i.e., hypotension or requirement for transfu-
ion) and endoscopic hemostasis is difficult to achieve, all
latelet antagonists should be withheld for 3 to 5 days to
educe the likelihood of early rebleeding. If complete
essation is not advisable, temporary transition to a single
gent might attenuate the risk of rebleeding. Although
ome cardiologists prefer clopidogrel over aspirin as a
emporary monotherapy, the only available head-to-head
omparison of aspirin versus clopidogrel monotherapy re-
ealed only a modest benefit for the latter (97).
Endoscopist experience has been shown to lessen bleed-
ng complications associated with colonoscopy, and this is
ikely true for other procedures as well. There are few
trategies, from the technical standpoint, that reduce bleed-
ng risk, other than avoiding excessive tissue injury during
he diagnostic or therapeutic intervention. Nevertheless,
xperience and skill across a wide range of endoscopic
herapies likely offers real benefit that is difficult to quantify
y outcome studies. Thus, the sickest patients will benefit
ost from the wisdom and skill of an experienced endos-
opist who balances successfully both the GI and CV risks.
ummary. Platelet-directed pharmacotherapy with aspirin
nd, among patients experiencing ACS and/or those under-
oing PCI and stent placement, a thienopyridine represents
he current standard of care. Existing guidelines provided by
he American College of Cardiology/American Heart Associ-
tion, European Society of Cardiology, and American College
f Chest Physicians underscore the benefit of dual platelet
ntagonists in patients at high risk for thrombotic events and
he potential detrimental effects of sudden drug cessation—
articularly within the first 6 months after PCI with DES
nsertion. Accordingly, elective endoscopic procedures should
e deferred during this time period and possibly up to 12
onths, if clinically acceptable. Procedures scheduled beyond 6
onths, particularly those associated with heightened bleeding
isk, could be undertaken 5 to 7 days after thienopyridine drug
essation. If possible, aspirin should be continued.
Whether a modified approach will be needed for patients
eceiving prasugrel, a thienopyridine platelet antagonist
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han clopidogrel and ticlopidine, is currently unknown.
After the procedure, and once hemostasis has been
chieved, a thienopyridine can be resumed either with or
ithout an initial oral loading dose, depending on the
nticipated risk for thrombosis and delayed bleeding.
latelet-directed pharmacotherapy should be continued for
atients undergoing elective endoscopic procedures known
o pose a low risk for bleeding (Table 3).
There are few strong indications for platelet bridging ther-
py among patients undergoing elective endoscopic proce-
ures. Bridging with anticoagulants (as a substitute for platelet
ntagonists), given the absence of supportive data, does not
ave a place in periprocedural patient management. The only
urrently available platelet antagonist that could be used for this
pecific purpose is eptifibatide, an intravenously administered
lycoprotein IIb/IIIa receptor inhibitor. Evidence-based rec-
mmendations are not available.
Endoscopist experience is known to lessen bleeding
omplications related to colonoscopy and potentially for
ther elective GI procedures as well. The potential for
omplications associated with high-risk endoscopic proce-
ures can be reduced by avoiding excessive tissue injury
uring the procedure, sound technical skills, and good
linical judgment.
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A Practical Approach to Managing
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